NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Ophthalmic Therapeutics M&A update, 14–28 September 2026

A bi-weekly update on Ophthalmic Therapeutics covering public market moves, major regulatory and legal catalysts, and M&A activity across 12 covered names for September 14–28, 2026. Built for operators, acquirers and advisors tracking the sector's clinical readout calendar and deal record.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Ophthalmic Therapeutics Sector Outlook — September 2026

Key figures

Sector median move
-6.2%
close-to-close, Sep 14–28
S&P 500 return
+0.8%
same window
Kodiak Sciences (KOD) move
+171.3%
two-week window
Sector EV/Revenue median
4.2x
NeuraCap standing valuation lens

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › OPHTHALMIC THERAPEUTICS

One Pivotal Readout Resets the Wet AMD Race While the Sector Slides

This update covers what moved, what companies announced and what it means in Ophthalmic Therapeutics over September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Ophthalmic Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

Over September 14–28, 2026, 10 of 12 covered Ophthalmic Therapeutics names fell, with a sector median move of -6.2% against a +0.8% S&P 500 return, concentrating weakness inside the sector. Kodiak Sciences Inc. (KOD) rose +171.3% on pivotal wet AMD Phase 3 results, and Surrozen, Inc. (SRZN) gained +66.1% on an FDA IND filing, while Premium-tier names like Ocular Therapeutix, Inc. (OCUL) fell -28.5%. No new M&A transactions were recorded in the window against a sector EV/Revenue median of 4.2x.

Key findings

  • 10 of 12 covered names fell; sector median -6.2% vs S&P 500 +0.8%
  • Kodiak Sciences surged +171.3% on wet AMD Phase 3 readout
  • Surrozen jumped +66.1% after FDA IND filing for diabetic macular edema
  • No M&A transactions recorded in the window; sector EV/Revenue median 4.2x

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › OPHTHALMIC THERAPEUTICS

    This is the cover slide introducing the Ophthalmic Therapeutics bi-weekly update for September 14–28, 2026.

    We open with the headline: a single wet AMD readout reset the sector while the broader market held steady. This report walks through what moved, what companies announced, what transacted, and what it means for Ophthalmic Therapeutics over September 14–28, 2026.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › OPHTHALMIC THERAPEUTICS One Pivotal Readout Resets the Wet AMD Race While the Sector Slides This update covers what moved, what companies announced and what it means in Ophthalmic Therapeutics over September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Ophthalmic Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    Clinical and Regulatory Readouts, Not the Broad Market

    This slide summarizes the two-week period's bottom line across 12 covered names.

    Over the two-week window, 10 of 12 covered names fell, with a sector median move of -6.2% against a +0.8% return for the S&P 500. That gap tells us the weakness sat inside the sector rather than across the broader market. The period's story was binary: Kodiak Sciences Inc. (KOD) surged +171.3% on a pivotal wet AMD Phase 3 readout, and Surrozen, Inc. (SRZN) rose +66.1% on an FDA IND filing, while Premium-tier names like Ocular Therapeutix, Inc. (OCUL) fell -28.5%. So what: this is a readout-driven market, and positioning around the clinical calendar mattered more than sector beta.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE Clinical and Regulatory Readouts, Not the Broad Market The two-week period in one page · 12 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Ophthalmic Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 10 of 12 Covered Names Fell; The Median Move Was -6.2% The S&P 500 returned +0.8% over the same window, so the weakness sat inside the sector rather than across the market. 2 A Pivotal Wet AMD Readout Carried the Whole Period Kodiak Sciences Inc. (KOD) ended the two-week period +171.3%, with its largest day on Sep 28 at +178.0%, following topline results from the DAYBREAK pivotal Phase 3 study of Zenkuda and KSI-501. Barron's reported the company plans to file for regulatory approval of Zenkuda. 3 A First Regulatory Step Was Enough to Double a Small Developer in a Day Surrozen, Inc. (SRZN) gained +66.1% over the window and +108.4% on Sep 24, reported alongside its submission of an Investigational New Drug application to the FDA for SZN-8141 in diabetic macular edema. 4 The Declines Were Concentrated in Names the Market Already Prices High Ocular Therapeutix, Inc. (OCUL), a Premium-tier name in NeuraCap's standing view, fell -28.5%, with a -20.6% day on Sep 28. EyePoint Pharmaceuticals, Inc. (EYPT) fell -22.1% and Oculis Holding AG (OCS) fell -14.5%. +171.3% Best mover — Kodiak Sciences Inc. (KOD) worst: OCUL -28.5% · 2 up / 10 down of 12 covered -6.2% Sector median two-week return vs S&P 500 +0.8%

  3. 03
    PUBLIC MARKET MOVERS

    Binary Readouts Did the Work in Both Directions

    This slide shows which public stocks moved most and why, close-to-close over the window.

    Binary readouts did the work in both directions this period, with a materiality bar of +14.1% sector-relative separating signal from noise. Kodiak Sciences Inc. (KOD) closed the window +171.3%, including a +178.0% single-day move on Sep 28 tied to topline DAYBREAK Phase 3 results for Zenkuda and KSI-501. Surrozen, Inc. (SRZN) gained +66.1% over the window and +108.4% on Sep 24 following its IND submission for SZN-8141. On the other side, Ocular Therapeutix, Inc. (OCUL) fell -28.5%, EyePoint Pharmaceuticals, Inc. (EYPT) fell -22.1%, and Oculis Holding AG (OCS) fell -14.5%. So what: the market is pricing clinical and regulatory milestones directly, and Premium-tier valuations gave the largest decliners the least cushion.

    Everything on this page

    PUBLIC MARKET MOVERS Binary Readouts Did the Work in Both Directions Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -6.2% · S&P 500 +0.8% · materiality bar ±14.1% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Ophthalmic Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -6.2% Kodiak Sciences Inc. (KOD) +171.3% Shares moved following the September 28 topline results from the DAYBREAK pivotal Phase 3 study of Zenkuda and KSI-501 in wet AMD; Barron's reported the company plans to file for approval of Zenkuda. In retina, a clean pivotal win can re-rate a pre-commercial developer in a single session. COMPANY-SPECIFIC Surrozen, Inc. (SRZN) +66.1% The move appears to reflect the company's submission of an Investigational New Drug application to the FDA for SZN-8141 in diabetic macular edema, reported September 24. Surrozen also presented at a healthcare conference on September 16. Entry into diabetic macular edema draws attention at the earliest regulatory step, not only at readout. COMPANY-SPECIFIC Ocular Therapeutix, Inc. (OCUL) -28.5% No notable in-window news was identified that clearly explains the move. At -28.5%, the decline was well below the -6.2% median move across covered names. Premium-tier names carry the highest embedded expectations and travel furthest in both directions. UNEXPLAINED EyePoint Pharmaceuticals, Inc. (EYPT) -22.1% The available evidence points to the September 15 notice that Pomerantz LLP is investigating claims on behalf of EyePoint investors. The largest single day ran the other way, at +15.7% on Sep 17. A legal overhang can price into a developer's equity long before any claim is tested. COMPANY-SPECIFIC

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    Regulatory Milestones on One Side, Legal Notices on the Other

    This slide lists the period's highest-impact regulatory and legal news events.

    This period's highest-impact events split cleanly between regulatory milestones and legal notices, and every event on this page links back to its underlying filing or article. Kodiak Sciences Inc.'s DAYBREAK Phase 3 topline results and stated plan to file for Zenkuda approval anchored one side of the calendar, while Surrozen, Inc.'s FDA IND submission for SZN-8141 opened a new regulatory track. Each 'why it matters' line reflects our read of the recorded evidence, not a claim of cause and effect. So what: the catalyst calendar, not macro sentiment, is what clients should track next.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS Regulatory Milestones on One Side, Legal Notices on the Other The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Ophthalmic Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 18 · NEWS · GlobeNewsWire Ocular Therapeutix granted inducement equity to newly hired employees Inducement grants go to new hires, so the notice is a staffing signal from a company preparing an NDA submission — the stage where commercial build costs begin. Hiring ahead of approval is the earliest observable sign that a launch is being resourced. Sep 16 · NEWS · GlobeNewsWire EyePoint granted inducement equity to new hires in its retinal disease programmes The grants point to continued hiring at a developer of therapies for serious retinal diseases. Field-force build is the cost that precedes any buy-and-bill pull-through. Retina prescribers are concentrated, so a small specialist team built early can cover the account base. Sep 15 · NEWS · GlobeNewsWire Ocular Therapeutix cleared its pre-NDA meeting with the FDA for AXPAXLI in wet AMD The company said the meeting confirms its plan to submit the AXPAXLI NDA on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety, with submission on track for 4Q 2026. Clarity on the regulatory path, not incremental acuity data, is what carries a retina asset toward launch. Sep 17 · NEWS · PRNewsWire Pomerantz recirculated its investor-claims investigation notice on EyePoint The second release widened the reach of the same notice within the window, keeping the item in front of the market for several sessions. Repeat distribution of a single notice can extend its presence in the news flow well past day one. Sep 17 · NEWS · PRNewsWire Pomerantz recirculated its investor-claims investigation notice on LENZ Therapeutics A second release of the same notice kept the item live in the window and shows how quickly these notices propagate across wire services. Two of the period's covered names drew the same type of notice within days of each other. Sep 17 · NEWS · GlobeNewsWire An Oculis board member purchased ordinary shares, disclosed under managerial transaction rules A board-level purchase is a direct signal of how insiders view the company's own programme position, disclosed in a period when the shares traded down. Insider purchases are one of the few company-level signals available between clinical readouts.

  5. 05
    M&A & STRATEGIC ACTIVITY

    The Deal Record Stood Still While the Clinical Record Moved

    This slide reports on M&A and strategic activity, including precedent transaction context.

    The deal record stood still this period: zero new transactions against a precedent set of 20 recorded deals. That contrast with the clinical record's movement is itself the signal — capital allocation via M&A did not keep pace with the clinical news flow. NeuraCap's standing valuation lens for the sector remains EV / Revenue, with a sector median of 4.2x and a Premium-tier median of 18.5x, giving a fixed reference point for when deal activity resumes. So what: the next M&A conversation in this sector will likely be priced against a backdrop that has already re-rated on clinical news, not deal comps.

    Everything on this page

    M&A & STRATEGIC ACTIVITY The Deal Record Stood Still While the Clinical Record Moved September 14–28, 2026 · precedent transactions: 20 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Ophthalmic Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. Buyers continue to reference the 20 precedent transactions already carried in the record, priced on asset-level cash flows rather than on a market multiple. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 20 Recorded precedent transactions the reference set buyers and sellers price against

  6. 06
    WHAT IT MEANS

    What a Readout-Driven Two-Week Period Changes for Operators, Buyers and Advisors

    This slide translates the period's events into implications for operators, acquirers and advisors.

    For owners and operators, this period rewarded durability of effect and dosing interval as the operating KPIs behind the largest moves. For acquirers, the wet AMD reference set gained a data point: Kodiak Sciences Inc. (KOD) moved toward a stated regulatory filing plan, and Surrozen, Inc. (SRZN) opened a diabetic macular edema programme at the FDA. For advisors, the lesson is to lead with the readout calendar rather than the index, since 10 of 12 covered names fell while the S&P 500 returned +0.8%. So what: these are observations drawn from recorded evidence, not recommendations, but they point toward where the next re-rating is likely to originate.

    Everything on this page

    WHAT IT MEANS What a Readout-Driven Two-Week Period Changes for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Ophthalmic Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2026E) median 4.2x 14 companies in the study 3 valuation tiers Standing thesis: Ophthalmic therapeutics splits in two: clinical-stage programme owners and a sterile ophthalmic supply business FOR OWNERS & OPERATORS Durability Is the KPI the Period Rewarded Dosing interval and durability of effect, injection burden per patient per year and retina specialist account penetration are the operating measures behind this period's largest moves. FOR ACQUIRERS The Reference Set in Wet AMD Just Gained a Data Point Kodiak Sciences Inc. (KOD) moved from pre-readout to a stated plan to file for approval of Zenkuda, and Surrozen, Inc. (SRZN) opened a diabetic macular edema programme at the FDA. Ocular Therapeutix, Inc. FOR ADVISORS Lead with the Readout Calendar, Not the Index 10 of 12 covered names fell while the S&P 500 returned +0.8%, and both gainers were driven by clinical or regulatory progress.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    This slide explains the sources and methodology behind the update's figures.

    Every figure in this update links back to the record it was taken from, and the sources drawn on for the period are listed on this page. Market data runs through September 28, 2026, and driver attributions use calibrated language reflecting our read of the recorded evidence rather than asserted causation. So what: clients can trace any number in this deck back to its source before acting on it.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Ophthalmic Therapeutics Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 2 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T181931Z_559_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: globenewswire.com · prnewswire.com

Sources and methodology

This update covers Ophthalmic Therapeutics over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 12 listed companies whose core business is Ophthalmic Therapeutics under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Belite Bio, Inc (BLTE), EyePoint Pharmaceuticals, Inc. (EYPT), Harrow Health, Inc. (HROW), Kodiak Sciences Inc. (KOD), LENZ Therapeutics, Inc. (LENZ), Molecular Partners AG (MOLN), Oculis Holding AG (OCS), Ocular Therapeutix, Inc. (OCUL), Regeneron Pharmaceuticals, Inc. (REGN), Surrozen, Inc. (SRZN), Tarsus Pharmaceuticals, Inc. (TARS), Viridian Therapeutics, Inc. (VRDN). 2 names below the floor were excluded from the statistics: ALDX, OKYO.

Window and company universe

This update covers Ophthalmic Therapeutics over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 12 listed companies whose core business is Ophthalmic Therapeutics under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Belite Bio, Inc (BLTE), EyePoint Pharmaceuticals, Inc. (EYPT), Harrow Health, Inc. (HROW), Kodiak Sciences Inc. (KOD), LENZ Therapeutics, Inc. (LENZ), Molecular Partners AG (MOLN), Oculis Holding AG (OCS), Ocular Therapeutix, Inc. (OCUL), Regeneron Pharmaceuticals, Inc. (REGN), Surrozen, Inc. (SRZN), Tarsus Pharmaceuticals, Inc. (TARS), Viridian Therapeutics, Inc. (VRDN). 2 names below the floor were excluded from the statistics: ALDX, OKYO.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 20 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Ophthalmic Therapeutics?

Company valuation reports run the same method against a single business — public or private.